Teclistamab‐cqyv in multiple myeloma

Abstract

Multiple myeloma (MM) is an incurable neoplasm characterized by significant morbidity and mortality. Despite advances in treatment, MM patients eventually experienced a relapse of the disease. Penta‐drug refractory patients continue to be the hard core of relapsed/refractory (RR) settings. Teclistamab‐cqyv is a humanized IgG4 antibody and a bispecific BCMA‐director CD3 T‐cell engager. It recruits endogenous T cells, by targeting CD3 receptors expressed on their surface, resulting in their activation against BCMA, an antigen expressed by plasma cells. US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have approved Teclistamab‐cqyv in monotherapy for the treatment of RRMM patients who have received at least three prior therapies, including immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and anti‐CD38 monoclonal antibodies (MoAbs) and have demonstrated disease progression during the last therapy. Its effectiveness was demonstrated in a pivotal clinical trial where the overall response rate (ORR) reached 60%. Other clinical studies are currently ongoing to investigate the association of the bispecific antibody with novel drugs with encouraging preliminary results, especially in the setting of heavily pretreated patients. In this review, the authors will provide a comprehensive overview of the drug, including its mechanism of action, major clinical trials, and future perspectives.

Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow‐up of a multicenter, retrospective real‐world experience with 321 cases outside of controlled clinical trials

“…Consequently, new therapeutic strategies are mandatory. Promising approaches include CAR T-cell therapies, 22 such as idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), the bispecific antibody teclistamab, 23 and anti-BCMA antibody-drug conjugate belantamab mafodotin 24. Moreover, ongoing clinical trials are exploring the efficacy of combining elotuzumab with other anti-myeloma drugs such as iberdomide (CC-220), 27 isatuximab, 28 and belantamab 29…”

“…In contemporary medical practice, the therapeutic repertoire of RRMM is continuously evolving. Alongside established PIs and IMIDs, emerging modalities such as chimeric antigen receptor (CAR) T-cell therapies, 22 bispecific antibodies, 23 and monoclonal antibodies, 24 represent a transformative shift, fundamentally reshaping treatment strategies for MM patients. Within clinical settings, patients who have received two prior lines of therapy may derive benefit from two The present study described an Italian cohort of RRMM patients treated with EloPd, featuring an extended follow-up period and encompassing a larger cohort size.…”

Applied Cardio-Oncology in Hematological Malignancies: A Narrative Review

“…Treatment-related adverse events have occurred, particularly CRS and ICANS (immune effector cell-associated neurotoxicity syndrome), but less frequently and less severely compared with CAR T-cell therapy. Cardiovascular complications are due to CRS: hypertension (18%), hypotension (12%), and cardiac arrhythmias (16%) [55,56].…”